Outcomes of XEN 63 Device at 18-Month Follow-Up in Glaucoma Patients: A Two-Center Retrospective Study.

Antonio Maria FeaMartina MenchiniAlessandro Rossi Chiara PosarelliLorenza MalinverniMichele Figus

Published in: Journal of clinical medicine (2022)

The XEN63, either alone or in combination with cataract surgery, significantly lowered the IOP and reduced the need for ocular hypotensive drugs over a period of 18 months.

Keyphrases

cataract surgery
end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
adipose tissue
optical coherence tomography